Altimmune (NASDAQ:ALT) Stock: Insider Wayne Pisano Buys 10,000 Shares

Altimmune, Inc. (NASDAQ:ALT) Director Wayne Pisano bought 10,000 shares of the firm’s stock in a transaction dated Friday, November 13th. The shares were purchased at an average price of $1.64 per share, with a total value of $16,400.00. Following the acquisition, the director directly owned 58,800 shares in the company, valued at approximately $96,432. This trade represents a 20.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Altimmune Trading Up 2.8%

ALT traded up $0.04 on Friday, reaching $1.66. 3,501,696 shares of the company’s stock were exchanged, compared to its average volume of 4,245,085. The company’s 50 day moving average is $2.62 and its 200-day moving average is $3.17. The company has a market cap of $321.93 million, a price-to-earnings ratio of -2.12 and a beta of 0.16. Altimmune, Inc. has a twelve month low of $1.58 and a twelve month high of $6.44. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities analysts predict that Altimmune, Inc. will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after acquiring an additional 762,223 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Altimmune during the second quarter valued at approximately $2,097,000. Bank of America Corp DE raised its stake in shares of Altimmune by 48.6% during the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after purchasing an additional 186,420 shares during the period. Hennion & Walsh Asset Management Inc. raised its stake in shares of Altimmune by 156.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock valued at $1,575,000 after purchasing an additional 316,209 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Altimmune by 69.4% during the second quarter. Wellington Management Group LLP now owns 420,300 shares of the company’s stock worth $1,278,000 after purchasing an additional 172,142 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

More Altimmune News

Investors following ALT have been watching these news items:

• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments at September 30, with a stated runway through the PERFORMA readout and into 2029—an important buffer for its clinical programs. Article
• Positive Sentiment: B. Riley reaffirmed its “buy” rating, signaling continued analyst support. Article
• Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 consensus estimate. Higher research and development costs are pressuring results, and investors remain focused on the capital required to advance the pipeline despite the reported cash runway. Article

Analyst Ratings Changes

A number of brokerages have recently commented on ALT. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Friday. B. Riley Financial reaffirmed a “buy” rating on shares of Altimmune in a research report on Friday. Evercore reiterated an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.33.

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.